Placebo Controlled, Randomized, Double-blind, Multi-center, Multinational Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 Given Intravenously in Patients With Decompensated Chronic Congestive Heart Failure.

Trial Profile

Placebo Controlled, Randomized, Double-blind, Multi-center, Multinational Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 Given Intravenously in Patients With Decompensated Chronic Congestive Heart Failure.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Cinaciguat (Primary)
  • Indications Decompensated heart failure; Heart failure
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 17 Jun 2009 Planned number of patients changed from 210 to 149 as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Actual initiation date changed from Nov 2007 to Dec 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top